Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis

Henoch-Schonlein Purpura Nephritis Clinical Trial

— CSTCMDTCHSPN  

Official title:

Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02878018
• Other study ID #: ZJ16813
• Status: Active, not recruiting
• Start date: September 2016
• Est. completion date: May 2020

Study information

• Verified date: March 2019
• Source: Liaoning University of Traditional Chinese Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Henoch-Schonlein purpura nephritis(HSPN) is one of the most common secondary glomerulonephritis in children. A large, prospective, multicenter cohort study is being conducted in three institutions. Eligible Henoch-Schönlein purpura nephritis children will be classified as the experimental group (n=300) and the control group (n=300) based on the interventions they receive. Patients taking Chinese herbal formula will be in the experimental group, and those taking Western medicine will be in the control group. The entire study will last 60 weeks, including a 12-week observation period and a followup at 12 months.

Description:

Background: Henoch-Schönlein purpura nephritis involves the renal impairment of Henoch-Schönlein purpura and can easily relapse into life-threatening late nephropathy in severe cases. Although there is a lack of validated evidence for its effectiveness, traditional Chinese medicine is the most commonly used method in China to treat Henoch-Schönlein purpura nephritis. We report the protocol of a prospective cohort trial using traditional Chinese medicine to investigate the effectiveness, safety and advantages for children with Henoch-Schönlein purpura nephritis.

Methods/Design: A large, prospective, multicenter cohort study is being conducted in three institutions. Eligible Henoch-Schönlein purpura nephritis children will be classified as the experimental group (n=300) and the control group (n=300) based on the interventions they receive. Patients taking Chinese herbal formula will be in the experimental group, and those taking Western medicine will be in the control group. The entire study will last 60 weeks, including a 12-week observation period and a followup at 12 months. Seven visits will be scheduled for each participant with visits in week 0, week 2, week 4, week 6, week 8, week 10 and week 12. The primary outcomes include the remission rate and the recurrence rate. The secondary outcomes include the urine erythrocyte effectiveness, the urine protein effectiveness, the hormone usage rate, the immunosuppressant usage rate, and the incidence rate of renal failure. Safety outcomes and any adverse reactions will be recorded during the study.

Discussion: This study will determine whether the Chinese herbal formula is helpful for treating Henoch-Schönlein purpura nephritis in children. The findings will provide a basis for further confirmatory studies.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 600
• Est. completion date: May 2020
• Est. primary completion date: March 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 18 Years

Eligibility

Inclusion criteria

1. A diagnosis of HSPN as well as three major constitution types (Heat-Toxin, Wet-Heat, Qi-Deficiency with Blood-Stasis) according to WM and TCM.

2. Age: 5 to 18 years old (including 5 and 18 year-olds).

3. The clinical classification of HSPN includes isolated hematuria, insolated proteinuria, hematuria with proteinuria, and acute glomerulonephritis.

4. The ability to provide detailed connection and complete a followup.

5. The ability to understand and sign a written informed consent.

Exclusion criteria

1. HSPN with renal insufficiency.

2. A clinical classification of HSPN that includes nephritic syndrome, rapidly progressive glomerulonephritis and chronic glomerulonephritis.

3. Suffering from serious complications, such as respiratory, digestive, hematological or liver diseases.

4. Tumor, infectious diseases, or mental disorders.

5. Allergic to TCM use.

6. No prescribed medication, poor compliance, or incomplete data affecting the efficacy and safety of these judgments.

7. A history of another clinical trial in the previous 2 weeks.

8. No consent form signed.

Related Conditions & MeSH terms

• Henoch-Schonlein Purpura Nephritis
• Nephritis
• Purpura
• Purpura, Schoenlein-Henoch

Intervention

Drug:
• Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula
Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
• angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant
prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.

Locations

Country	Name	City	State
China	Zhang Jun	Shenyang	Liaoning

Sponsors (3)

Lead Sponsor	Collaborator
Liaoning University of Traditional Chinese Medicine	First Hospital of China Medical University, Shengjing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urine protein	Recovery:Urine protein(-).; Marked effect:Urine protein reduces by 2'+'.; Effective:Urine protein reduces by 1'+'.; Ineffective:Urine protein has no changes.	2 weeks
Primary	24-hour urinary protein excretion	Recovery:24-hour urinary protein excretion is normal.; Marked effect:24-hour urinary protein excretion reduction is larger than 50%.; Effective:24-hour urinary protein excretion reduction is smaller than 50%.; Ineffective:24-hour urinary protein excretion has no changes.	2 weeks
Primary	Urine erythrocyte	Recovery:Urine erythrocyte is normal.; Marked effect:Urine erythrocyte reduction is larger than 50%.; Effective:Urine erythrocyte reduction is smaller than 50%.; Ineffective;Urine erythrocyte has no changes.	2 weeks
Primary	Creatinine clearance rate and Serum creatinine	Diagnostic criteria of chronic renal failure: Creatinine clearance rate<80ml/min; Serum creatinine>133µmol/L; The patient who have a history of chronic kidney diseases or systemic diseases involving kidney.	1 year
Secondary	Number of patients with hormone therapy	Hormone utilized rate=Number of patients with hormone therapy/The total number of patients	3 months
Secondary	Number of patients with immunosuppressant therapy	Immunosuppressant utilized rate=Number of patients with immunosuppressant therapy/The total number of patients	3 months